Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice.
Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice. J Dermatolog Treat. 2018 Dec 08;:1-4 Authors: Chiricozzi A PMID: 30526155 [PubMed - as supplied by publisher]
Abstract Psoriasis affects 1-3% of the population and up to 1/3 of psoriasis patients have underlying psoriatic arthritis (PsA)1 . Non-specific musculoskeletal complaints are even higher, being around 50%2 . Detecting early signs of PsA and early treatments are crucial to improve the outcomes to prevent progressive, damaging arthritis3 . Due to the high frequency of non-specific pain in psoriasis, it is not possible for every psoriasis patient with joint pain to be assessed by a rheumatologist. PMID: 31505032 [PubMed - as supplied by publisher]
ObjectiveTo evaluate the associations of C ‐reactive protein (CRP) and circulating Th17‐associated cytokine levels with psoriatic arthritis (PsA) disease activity and therapeutic response to ustekinumab.MethodsInterleukin ‐17A (IL‐17A), IL‐17F, IL‐23, and CRP concentrations were measured in serum samples collected as part of the 2 PSUMMIT phase III studies of ustekinumab in PsA (n = 927). In post hoc analyses, relationships of IL‐17A, IL‐17F, and CRP levels at baseline, week 4, and week 24 with baseline s kin and joint disease activity and response to therapy were evaluated using generalized linear models a...
Psoriasis developed through abnormal crosstalk between the immune cells and epidermal keratinocytes. Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor and has been approved for the treatment of patients with plaque psoriasis and psoriatic arthritis. Cyclic adenosine monophosphate (cAMP) has a significant role as a secondary messenger and PDE4 degrades intercellular cAMP to AMP. It is widely recognized that PDE4 inhibition by Apremilast increases intracellular cAMP levels in immune cells, thereby in turn suppress the expression of proinflammatory cytokines, such as TNF- α, IFN-γ and IL-23, which are all...
We are performing omic analyses of psoriasis and psoriatic arthritis (PsA) patients to address the hypothesis that biomarker discovery will inform more individualized care of individuals (endotypes) with psoriasis and their comorbidities. We collected whole blood from psoriasis patients (n=59, 16 PsA; mean PASI=8.6 (range 0-33.5) with 9 healthy controls) and PBMCs (n=9 psoriasis, n=5 controls). RNASeq was performed using Illumina TruSeq Total RNA kits and a NextSeq 550 (15M+ paired reads/sample, 75 bp).
Ustekinumab, a monoclonal antibody that targets interleukin (IL)-12/23, is used to treat psoriasis, psoriatic arthritis and Crohn disease. In 2011, a meta-analysis of randomized trials alerted on a potential risk of major adverse cardiovascular events (MACE) within the first months after the initiation of anti-IL-12/23 antibodies. Our objective was to assess if ustekinumab initiation may trigger MACE. Using the French National Health Insurance database, covering 66 million subjects, we included all patients exposed to ustekinumab between 2010 and 2016, classified according to their cardiovascular risk level (high vs.
The objective of this study was to explore whether plasma-derived EV microRNAs may serve as biomarkers for PsA in patients with psoriasis.
Conclusions: Serum lipocalin-2 concentrations are higher in psoriasis/PsA patients than controls. However, more large-scale studies are warranted to explore the association between serum lipocalin-2 and the pathogenetic mechanisms of psoriasis/PsA. PMID: 31467617 [PubMed - in process]
CONCLUSION: (1) Both immune disorder and bone metabolic dysregulation could be the shared mechanism in the development of PsA, PV, RA, and GA. (2) Immune dysfunction is involved in GA. Our study may shed new light on the diagnosis and treatment strategy of these autoimmune diseases and GA, which warrants further studies. PMID: 31465725 [PubMed - in process]
The interleukin-17A inhibitor is now indicated for the treatment of adults with active ankylosing spondylitis, as well as for certain patients with plaque psoriasis and active psoriatic arthritis.FDA Approvals
Innovative Therapy Will Strengthen Amgen's Inflammation Portfolio for Patients Around the World Acquisition Expected to Accelerate Growth and Enhance Value for Amgen Shareholders Amgen to Host Call With Investors at 5 a.m. PT (8 a.m. ET) THOUSAND ... Biopharmaceuticals, Acquisitions Amgen, Celgene, Otezla, apremilast, psoriasis, psoriatic arthritis